TransMedics Group (TMDX) Stock Price, News & Analysis

Company Overview

TransMedics Group, Inc. is a medical technology company focused on the development and commercialization of organ care systems designed to improve the preservation and viability of donor organs for transplantation. The company’s core technology, the Organ Care System (OCS) platform, enables continuous perfusion of organs with oxygenated, nutrient-rich solutions under near-physiologic conditions. By maintaining organs in a functioning state outside the human body, TransMedics aims to extend preservation times, enhance organ assessment, and increase the pool of available donor organs.

The OCS platform currently encompasses systems tailored for lung, heart and kidney transplantation. The OCS Lung System, cleared by the U.S. Food and Drug Administration (FDA) and CE-marked in Europe, supports ex vivo lung perfusion to assess and rehabilitate marginal donor lungs. The OCS Heart System, which received FDA approval in 2021, employs normothermic perfusion to maintain the heart in a beating state, allowing transplant teams to evaluate cardiac function before implantation. TransMedics is also advancing its kidney perfusion technology, with clinical trials underway to demonstrate benefits in extending preservation times and improving post-transplant outcomes.

Headquartered in Andover, Massachusetts, TransMedics has established a growing presence across North America, Europe and select markets in Asia. The company collaborates with leading transplant centers and health authorities to integrate its perfusion technology into clinical practice. In addition to its proprietary hardware, TransMedics provides specialized disposables and perfusion solutions, training programs for surgical teams and ongoing technical support to promote the adoption of organ perfusion protocols worldwide.

Founded in 2005, TransMedics was co‐founded by physician-engineers committed to addressing critical gaps in organ transplantation. Today, Dr. Waleed Hassanein serves as President and Chief Executive Officer, guiding the company’s strategic vision for expanding indications and advancing clinical evidence. Under the leadership of CFO William Brennan and a seasoned executive team, TransMedics continues to invest in research and development, with the aim of transforming transplant medicine and improving patient outcomes.

Key Stats

• Today's Range: $109.66 to $114.63
• 50-Day Range: $111.50 to $143.04
• 52-Week Range: $55.00 to $177.37
• Volume: 789,501 shs
• Average Volume: 1.38 million shs
• Market Capitalization: $3.72 billion
• P/E Ratio: 80.79
• Dividend Yield: N/A
• Price Target: $129.88
• Consensus Rating: Moderate Buy

TransMedics Group Stock Analysis - MarketRank™

TransMedics Group scored higher than 42% of companies evaluated by MarketBeat, and ranked 692nd out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

TransMedics Group has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

TransMedics Group has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 43.00%

Earnings Growth

Earnings for TransMedics Group are expected to grow by 43.00% in the coming year, from $1.00 to $1.43 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of TransMedics Group is 80.79, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 26.50.

Price to Earnings Ratio vs. Sector

The P/E ratio of TransMedics Group is 80.79, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.06.

Price to Book Value per Share Ratio

TransMedics Group has a P/B Ratio of 16.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

25.56% of the float of TransMedics Group has been sold short.

Short Interest Ratio / Days to Cover

TransMedics Group has a short interest ratio ("days to cover") of 7.9.

Change versus previous month

Short interest in TransMedics Group has recently increased by 2.29%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

TransMedics Group does not currently pay a dividend.

Dividend Growth

TransMedics Group does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

25.56% of the float of TransMedics Group has been sold short.

Short Interest Ratio / Days to Cover

TransMedics Group has a short interest ratio ("days to cover") of 7.9.

Change versus previous month

Short interest in TransMedics Group has recently increased by 2.29%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.97

News Sentiment

TransMedics Group has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 13 news articles for TransMedics Group this week, compared to 18 articles on an average week.

Search Interest

16 people have searched for TMDX on MarketBeat in the last 30 days. This is an increase of 60% compared to the previous 30 days.

MarketBeat Follows

Only 4 people have added TransMedics Group to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, TransMedics Group insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,512,613.00 in company stock.

Percentage Held by Insiders

Only 7.00% of the stock of TransMedics Group is held by insiders.

Percentage Held by Institutions

99.67% of the stock of TransMedics Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TMDX Stock Analysis - Frequently Asked Questions

How have TMDX shares performed this year?

TransMedics Group's stock was trading at $62.35 at the start of the year. Since then, TMDX stock has increased by 76.2% and is now trading at $109.88.

How were TransMedics Group's earnings last quarter?

TransMedics Group, Inc. (NASDAQ:TMDX) posted its quarterly earnings data on Thursday, May, 8th. The company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.29 by $0.41. The business's revenue for the quarter was up 48.2% on a year-over-year basis.
Read the conference call transcript.

When did TransMedics Group IPO?

TransMedics Group (TMDX) raised $75 million in an initial public offering (IPO) on Thursday, May 2nd 2019. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and Canaccord Genuity were co-managers.

Who are TransMedics Group's major shareholders?

TransMedics Group's top institutional shareholders include Zevenbergen Capital Investments LLC (0.36%), Taylor Frigon Capital Management LLC (0.06%), State of Alaska Department of Revenue (0.06%) and Perigon Wealth Management LLC (0.06%). Insiders that own company stock include James R Tobin, Waleed H Hassanein, Miriam Provost, Stephen Gordon, Nicholas Corcoran, Tamer I Khayal, John F Carey, Anil P Ranganath, David Weill, Edward M Basile, Laura Damme and Stephanie Lovell.
View institutional ownership trends.

How do I buy shares of TransMedics Group?

Shares of TMDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of TransMedics Group own?

Based on aggregate information from My MarketBeat watchlists, some other companies that TransMedics Group investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Invesco QQQ (QQQ), Broadcom (AVGO), Arista Networks (ANET) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/18/2025
• Next Earnings (Estimated): 7/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:TMDX
• CIK: 1756262
• Web: www.transmedics.com
• Phone: (978) 552-0900
• Fax: N/A
• Employees: 210
• Year Founded: N/A

Price Target and Rating

• Average Price Target for TransMedics Group: $129.88
• High Price Target: $178.00
• Low Price Target: $75.00
• Potential Upside/Downside: +15.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.89
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.36
• Trailing P/E Ratio: 82.74
• Forward P/E Ratio: 112.52
• P/E Growth: N/A
• Net Income: $35.46 million
• Net Margins: 10.03%
• Pretax Margin: 10.25%
• Return on Equity: 21.88%
• Return on Assets: 6.15%

Debt

• Debt-to-Equity Ratio: 1.92
• Current Ratio: 9.10
• Quick Ratio: 8.32

Sales & Book Value

• Annual Sales: $441.54 million
• Price / Sales: 8.62
• Cash Flow: $1.63 per share
• Price / Cash Flow: 68.87
• Book Value: $6.81 per share
• Price / Book: 16.52

Miscellaneous

• Outstanding Shares: 33,820,000
• Free Float: 31,456,000
• Market Cap: $3.81 billion
• Optionable: Optionable
• Beta: 2.06